WHO ICTRP trial
AN OPEN-LABEL, SINGLE SEQUENCE, CROSSOVER DRUG-DRUG INTERACTION STUDY ASSESSING…
NL-OMON55479 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON55479 |
|---|---|
| Public title | AN OPEN-LABEL, SINGLE SEQUENCE, CROSSOVER DRUG-DRUG INTERACTION STUDY ASSESSING THE EFFECT OF PEXIDARTINIB ON THE PHARMACOKINETICS OF CYP3A4 AND CYP2C9 SUBSTRATES IN PATIENTS |
| Scientific title | AN OPEN-LABEL, SINGLE SEQUENCE, CROSSOVER DRUG-DRUG INTERACTION STUDY ASSESSING THE EFFECT OF PEXIDARTINIB ON THE PHARMACOKINETICS OF CYP3A4 AND CYP2C9 SUBSTRATES IN PATIENTS - PL3397-A-U126 |
| Primary sponsor | Daiichi Pharmaceutical |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom |
| Conditions | Cancer neoplasms;10040776;Cancer;neoplasms |
| Interventions | - tolbutamide reference treatment: single oral dose of tolbutamide (500 mg) on Day 1. - Midazolam reference treatment: single oral dose of midazolam (2 mg) on Day 1. - tolbutamide test treatment: single oral dose of tolbutamide (500 mg) on… |
| Registration date | Feb 18, 2021 |
| Target size | 3 |
| Secondary IDs | 2017-001687-38;NL62531.058.17 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: